METHOD FOR PREDICTING THE COURSE OF PRIMARY MEDIASTINAL B-LARGE CELL LYMPHOMA Russian patent published in 2022 - IPC G01N33/49 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncohematology, and can be used to predict the course of primary mediastinal B-large cell lymphoma. A blood test is carried out to determine the risk groups for early progression. At the outpatient stage, the number of leukocytes is determined in the general blood test. When the number of leukocytes is equal to or more than 9×10⁹/l, an unfavorable course of primary mediastinal B-large cell lymphoma is predicted.

EFFECT: method provides the possibility of predicting the course of primary mediastinal B-large cell lymphoma, which makes it possible to predict the possible outcome of the disease at the outpatient stage, due to the fact that the initial leukocytosis of patients is included as an additional high-risk criterion.

1 cl, 3 ex